Hong Kong Stock News

InSilico Medicine Cayman TopCo went into this earnings print with a growth label and a rich P/S multiple, yet the real story today is the profit swing hiding behind a relatively calm share price at HK$47.02. The stock has posted steady gains over the past three months and has not reacted violently to the latest numbers, even though the company moved from heavy losses in 2025 to a H1 2026 basic EPS of US$0.062 on US$106.303 million in revenue. For a high expectation biotech platform, that...

REPT BATTERO Energy stock closed at HK$10.24, with the market still treating it as a low multiple growth story rather than a proven earnings engine. Yet the latest half year numbers indicate this is now a profitability story. Basic earnings per share came in at ¥0.30 for the first half of 2026 and net income excluding extra items reached ¥703.85m, both backed by ¥14.92b in revenue from its battery business. The key point for investors is straightforward. The market price remains muted while...

Sihuan Pharmaceutical Holdings Group entered these results following a period of weak share price performance, with the stock down over the past week, month and quarter, yet trading on a rich P/E of 21x. That is a set up for emotional trading. The headline from this half year is simple. Profitability has firmed up, with basic earnings per share at C¥0.0249 on revenue of C¥1,161.2m. The tug of war now is between investors who are concerned about the valuation strain and those who see a company...

Seazen Group stock has quietly ground out a 7 day gain of about 4%. Today’s earnings story is less about the share price and more about pressure on the balance sheet. The headline is simple. Profit is in the black again with basic earnings per share of ¥0.08 for the first half of 2026, but the company is still carrying a thin net margin near 0.6% on the trailing 12 months and interest costs remain heavy. That clash between fragile profitability and financing strain is what the market is...

DPC Dash stock closed at HK$32.14 today, capping a rough few months with the share price down about 17% over 90 days. That reaction sits awkwardly against a business that just reported first half 2026 revenue of RMB 3,133.8m and trailing twelve month earnings per share of RMB 1.20. The real tension is not growth; it is margin pressure. Store level and adjusted EBITDA margins compressed as the business leaned hard into third party delivery platforms. Short term traders are focused on that...

Sinotruk (Hong Kong) stock has been grinding higher, with the share price up about 7% over the past week. Yet the real story sits in the trucks already sold and paid for. The latest half year shows heavy duty demand feeding into earnings power, with basic earnings per share at 1.58 CNY and net income of CNY 4,325.4m. The market still prices Sinotruk (Hong Kong) on a P/E of 12.4x, below both the Hong Kong machinery average and key peers. The headline from these results is simple: earnings...

Cirrus Aircraft stock has been grinding higher in recent weeks. Yet at HK$46.8 it still trades on a trailing P/E of 13.5x, well below the Asian aerospace and defense pack. Today's earnings drop one clear headline for investors: profit growth is still there, but net margin has slipped to 10.8% while one year earnings growth now trails the five year pace. The market is treating Cirrus Aircraft as a growth story priced like a laggard. The real question after this release is whether the margin...

Grand Pharmaceutical Group stock closed at HK$5.26, leaving shareholders with a small loss over the past week and only a modest gain over the past month. The market’s short term shrug came even as first half 2026 revenue reached HK$6,388.9m and basic earnings per share landed at HK$0.3031. The real story sits in profitability. Trailing net margin is 8.9% compared with 17.8% a year earlier, which keeps the focus on whether this earnings season marks a turning point in the margin squeeze or...

Build King Holdings ended Thursday at HK$1.47, with the stock roughly flat over the past week and weaker over three months, yet the new earnings paint a more complicated picture than the recent drift suggests. The headline from this half year is margin resilience. Net profit margin over the past year sat at 3.6%, ahead of the prior 3.1%, even as revenue for the latest half year came in at HK$5,961.3m. The tension for you as an investor is clear. The market is treating Build King Holdings like...

China Overseas Land & Investment came into this earnings season with a stock that had slipped about 9.3% over the last three months, yet it now trades around HK$14.17 and at roughly 12x P/E. The market is still treating it as a cautious value call in a stressed China property sector, but the latest half year numbers highlight pressure where it hurts most. Net profit margin over the past year is about 6.1% compared with 7.7% a year ago, so today’s headline is a margin squeeze story rather than...

Great Eagle Holdings just put a profit on the board and the stock is still stuck in reverse. Shares closed at HK$14.99, with the price down over the past week and month, even as the group swung from heavy losses to a Basic EPS of HK$0.44 for the first half of 2026. The headline is simple. A heavily discounted Hong Kong property stock that screens cheap on price to sales has finally printed a clean profit. The question now is whether investors are still anchored to last year’s steep losses or...

Harbin Electric stock closed at HK$16.28 after a choppy week, drifting slightly over the past seven days but still up over the past month. The market has been wrestling with how to price a business that now carries a single digit P/E while the shares trade above one discounted cash flow estimate. In that context, the latest half year earnings landed with one clear signal for investors. The headline is profit quality. Basic earnings per share for the first half of 2026 came in at C¥0.77,...

ANTA Sports Products entered this earnings day with the stock largely treading water. The 7 day return sat around 3.9% and the 90 day move was just over 2.6%. That is hardly the setup for a high conviction breakout. Then H1 2026 landed with revenue of ¥43,507m and basic earnings per share of ¥3.42, numbers that speak directly to how much profit the brand is pulling from each yuan of sportswear demand. The market now has to decide whether a trailing P/E of 11.6 and a trailing net margin of...

TransThera Sciences (Nanjing) stock came into this earnings print bruised, with the 90 day return deep in the red despite a small bounce over the past week and month. Yet the latest H1 2026 numbers tell a more nuanced story. Revenue landed at C¥35.455 million, a clear shift for a company that previously reported no sales, while earnings still showed a sizeable loss with basic earnings per share of C¥0.24 in the red. The real question for the market now is whether this early top line traction...

Shenzhen Expressway stock has drifted lower in recent months, even as many investors still treat it as a steady toll road cash machine. Q2 results challenge that comfort. Revenue came in at C¥1,893.5m with basic earnings per share of C¥0.154, and the latest trailing net profit margin sits at 12.3% compared with 14.1% a year earlier. The market is pricing Shenzhen Expressway at about 13.2x P/E, above peers, which sharpens the focus on this squeeze in profitability rather than on top line...

Robosense Technology came into this earnings print under pressure, with the stock down about 39% over the past three months, yet trading on a growth story that many investors still treat as intact. The market now has to square that narrative with Q2 numbers that show revenue of C¥560.999 million alongside another quarterly loss, with basic earnings per share of C¥0.21 in the red. For a high-growth lidar and sensing hardware player, the headline this quarter is simple: sales are holding up,...

Investors gave Zhejiang Taimei Medical Technology only a gentle nod after its half year report, with the stock near HK$5.54 and short term returns fairly flat. The headline story is not the share price. It is the renewed pressure on profitability in a business that is still scaling its medical technology platform. For the first half of 2026 Zhejiang Taimei Medical Technology reported revenue of C¥263.6m yet still booked a net loss of C¥45.1m and a basic earnings per share loss of C¥0.08. The...

ImmuneOnco Biopharmaceuticals (Shanghai) has ridden a strong wave of optimism into this earnings season, with the stock up about 39% over the past three months and closing at HK$4.08 on 27 August. The market is clearly paying for the story, not the profits, as the company still reported a loss in H1 2026 with basic earnings per share of C¥0.38 and net income of C¥164.19 million in the red. The key question for investors now is whether that premium P/S multiple of around 11.9x still feels...

Truly International Holdings closed at HK$0.82 today, roughly flat over the past week after a tough three months that left the stock down about 16%. The market reaction looks muted compared with the earnings story. The headline this half is pressure on profitability, not revenue scale. H1 2026 revenue came in at HK$6,960.2m, yet net income was only HK$101.6m, and the trailing net profit margin over the last year sat at 1.5%. With the stock on a 10.3x P/E and weak interest coverage, the key...

The market has grudgingly inched Dream International higher, with the stock up about 8% over the past week to HK$6.8. Yet the latest earnings lay bare a sharper squeeze on profitability that short term price action does not capture. Net profit margin over the past year sits at 9.4%, down from 13.4%, and headline basic earnings per share for the latest half year came in at HK$0.304. For anyone looking beyond today’s tick-by-tick moves, this margin pressure is the centre of gravity for the...

Luyuan Group Holding (Cayman) went into these H1 2026 results priced for perfection, with the stock on a rich 34x P/E and trading well above an estimated cash flow value of HK$4.80. Yet the headline numbers tell a tighter story. Revenue for the half year came in at ¥2,463.4m and net income reached ¥75.1m, keeping the earnings engine running but leaving very little room for disappointment at this valuation. For investors, the relationship between the premium price and the current level of...

Ausnutria Dairy stock closed at HK$1.20 today, barely moved over the past week, yet the earnings story feels anything but flat. The market is still treating the company as a lowly valued turnaround idea, but the latest half year results show a much heavier profit squeeze than that label suggests. Revenue in H1 2026 came in at ¥3,163.18m, yet the company reported a net loss of ¥705.05m and a basic loss per share of ¥0.3969. For a dairy producer that investors often assess on cash generation...

China Sanjiang Fine Chemicals closed at HK$3.865 on Thursday, capping a strong 30-day run. Yet the real story sits in the fresh H1 2026 earnings. Revenue reached C¥9,599.5m and basic earnings per share came in at C¥0.5686, which puts the stock on a trailing P/E of 5.1x, well below both the wider Hong Kong market and chemicals peers. That gap between a low earnings multiple and solid trailing profit growth is the tension investors now need to focus on. The short term share price strength is...

SSY Group went into this earnings print with the stock already up double digits over the past month, trading at a P/E above both peer and industry averages. The headline today is simple: the business delivered a heavier profit squeeze just as investors had been paying a premium for the stock. Net margin on a trailing basis is now 11.6%, down from 14.4% a year earlier, even as revenue sits at a 13.7% per year level. SSY Group is still framed around strong growth forecasts, but this set of...